Document is current
Any future updates will be listed below
-
Authors
Kosiborod, Mikhail http://orcid.org/0000-0002-3750-9789
Gomes, Marilia B.
Nicolucci, Antonio
Pocock, Stuart
Rathmann, Wolfgang
Shestakova, Marina V.
Watada, Hirotaka
Shimomura, Iichiro
Chen, Hungta
Cid-Ruzafa, Javier
Fenici, Peter
Hammar, Niklas
Surmont, Filip
Tang, Fengming
Khunti, Kamlesh
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02322762 at ClinicalTrials.govnct02226822 at ClinicalTrials.govDocuments that mention this clinical trial
Individualized HbA1c Targets in People with Type 2 Diabetes Initiating Second-Line Therapy—The Global DISCOVER Study
https://doi.org/10.2337/db18-1629-p
Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER
https://doi.org/10.2337/db18-1615-p
Temporal Trends in the Use of Sodium-Glucose Cotransporter 2 Inhibitors—The Global DISCOVER Study
https://doi.org/10.2337/db18-1141-p
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
https://doi.org/10.1136/bmjdrc-2020-001585
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
https://doi.org/10.1186/s12933-018-0787-8
Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
https://doi.org/10.1136/bmjopen-2019-034613
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Documents that mention this clinical trial
Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
https://doi.org/10.1007/s13300-021-01192-x
Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
https://doi.org/10.1007/s13300-017-0351-7
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
https://doi.org/10.1136/bmjdrc-2020-001585
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
https://doi.org/10.1186/s12933-018-0787-8
Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
https://doi.org/10.1136/bmjopen-2019-034613
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 30 July 2018
Accepted: 6 November 2018
First Online: 28 November 2018
